1
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., . . . Sabatine, M. S. (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 380(4), 347-357. doi:10.1056/NEJMoa1812389
2
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., . . . Zeiher, A. M. (2018). Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 379(22), 2097-2107. doi:10.1056/NEJMoa1801174
3
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., . . . Inzucchi, S. E. (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 373(22), 2117-2128. doi:10.1056/NEJMoa1504720
4
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., . . . Heineman, T. C. (2015). Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. New England Journal of Medicine, 372(22), 2087-2096. doi:10.1056/NEJMoa1501184
5
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., . . . Antman, E. M. (2013). Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 369(22), 2093-2104. doi:10.1056/NEJMoa1310907
6
Hokusai-VTE Investigators, B. H., Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. (2013). Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. New England Journal of Medicine, 369(15), 1406-1415. doi:10.1056/NEJMoa1306638
